A Study of JR-141 in Patients With Mucopolysaccharidosis II
Status:
Completed
Trial end date:
2019-10-04
Target enrollment:
Participant gender:
Summary
A Phase II open-label, randomized, parallel group, 2 sites (Brazil), designed to evaluate the
safety and efficacy of 3 doses of study drug for the treatment of the MPS II.